DNA Synthesis Technologies and Services Market, Distribution by Method of DNA Synthesis (Chemical Synthesis and Enzymatic Synthesis), Key Applications Areas (Research and Diagnostics and Therapeutic Applications), Company Size (Small, Mid-sized and Large), and Key Geographies (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    May 2022

  • Pages
    199

  • View Count
    1869

Example Insights

DNA-Synthesis-Technologies-and-Services-Market-Context-thumb DNA-Synthesis-Technologies-and-Services-Market-Services-Providers-thumb DNA-Synthesis-Technologies-and-Services-Market-DNA-Synthesis-thumb
DNA-Synthesis-Technologies-and-Services-Market-Distribution-of-Publications-thumb DNA-Synthesis-Technologies-and-Services-Market-Year-wise-Trend-thumb DNA-Synthesis-Technologies-and-Services-Market-Grant-Analysis
DNA-Synthesis-Technologies-and-Services-Market-Funding-and-Investments DNA-Synthesis-Technologies-and-Services-Market-Patent-Analysis-thumb DNA-Synthesis-Technologies-and-Services-Market-Application-Area-thumb

Overview

DNA or RNA molecules find a variety of applications in the biopharmaceutical industry for genetic testing, medical research, therapeutic development, forensic investigation, and other analytical processes. It is worth highlighting that several research studies are being conducted to evaluate the use of oligonucleotides, especially DNA, as a therapeutic intervention for treatment of various medical conditions. The approval of the first antisense oligonucleotide drug, Fomivirse, in 1998, led to a surge in the demand of DNA-based interventions. In addition to the application of DNA in therapy development, these entities are also being deployed in genetic diagnostics and have already proven their use in identifying patients across a diverse range of diseases including breast cancer, dyslexia, ovarian cancer, Parkinson’s disease and psoriasis. The advances in medical research have led to establishment of several technologies that can sequence, analyze, and edit different forms of DNA. This, coupled to the increasing use of DNA across diverse range of applications, have urged industry experts to actively look for efficient DNA synthesis technologies that not only facilitate parallelized synthesis of DNA but also provide unmatched precision, scalability, and speed. 

It is worth noting that several companies have developed proprietary enzymatic DNA synthesis platforms offering distinct advantages (such as the potential to increase length of DNA fragment, greater accessibility and convenience) over conventional DNA synthesis methods. Given the known merits of such technologies, a significant proportion of medical researchers and therapy / diagnostic developers prefer to outsource DNA synthesis operations to third party platforms / service providers who claim to provide the expertise in DNA synthesis and production. Presently, there are over 65 players that offer DNA synthesis technologies / services, and these players are actively undertaking efforts to build / expand their existing capabilities, in order to cater to the growing demand for DNA synthesis. Given the rising need for DNA across a wide range of applications, we are led to believe that the DNA synthesis platforms and services industry is likely to witness noteworthy growth in the foreseen future.

Scope of the Report

The “DNA Synthesis Technologies and Services Market, Distribution by Method of DNA Synthesis (Chemical Method and Enzymatic Method), Key Applications Areas (Research & Diagnostics and Therapeutic Applications), Company Size (Small, Mid-sized and Large), and Key Geographies (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global, 2022-2035” report features report features a detailed study of the current scenario and future potential of the DNA synthesis technologies and service providers. Further, the study underlines an in-depth analysis, highlighting the capabilities of service providers engaged in this domain. In addition to other elements, the study covers:  

  • A detailed assessment of the overall landscape of the DNA synthesis technologies and services market, providing information on type of offering, method of DNA synthesis (chemical method and enzymatic method), type of DNA molecule, custom offerings, and application area. Additionally, the report provides information on drug developer(s) involved in the domain, along with analyses based on a number of relevant parameters, such as year of establishment, company size and geographical location of headquarters.
  • Elaborate profiles of the key players involved in providing technologies and services in the DNA synthesis domain. Each profile features a brief overview of the company, its financial information, details on its technology / service portfolio, financial information, and recent developments and an informed future outlook.
  • A detailed overview of the current market landscape of oligonucleotide manufacturers focused on research and diagnostic applications, based on several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with information on the location of facility (country-wise), regulatory accreditations and certifications received, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, fill / finish, regulatory support, data analytics and reporting, and others) and type of modification(s) offered (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications and others).
  • A detailed overview of the current market landscape of oligonucleotide manufacturers focused on therapeutic applications, based on several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with information on the location of facility (country-wise), regulatory accreditations and certifications received, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, fill / finish, regulatory support, data analytics and reporting, and others) and type of modification(s) (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications and others).
  • An analysis of the partnerships established between various stakeholders in this domain, during the period 2017-2022, covering product development and commercialization agreements, R&D agreements, technology licensing agreements, other licensing agreements, mergers and acquisitions, and other relevant types of deals. 
  • A review of the funding and investments made in the domain, in the period between 2017 and 2022, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development. The analysis has been done on the basis of several parameters, such as number of funding instances, amount invested, type of funding, leading players and investors, and geographical analysis.
  • An in-depth analysis of grants that have been awarded to various research institutes for projects related to DNA synthesis technologies and services, in the period between 2017 and 2022, on the basis of important parameters, such as year of grant award, grant amount awarded, administering institute center, support period, type of grant application, grant activity code, emerging focus area, purpose of grant award, type of recent organization, popular NIH department and prominent program officers. 
  • A detailed review of more than 12,000 peer-reviewed, scientific articles related to research on DNA synthesis technologies, which have been published between 2017 and 2022, including analysis based on parameters, such as year of publication, key focus area, type of article, popular keywords, popular authors, therapeutic area, geography and key journals (in terms of number of articles published in this domain and impact factor of the journal).
  • An in-depth analysis of the patents related to DNA synthesis technologies, filed / granted till 2022, based on various parameters, such as patent publication year, geographical location / patent jurisdiction, CPC symbols, emerging focus areas, and type of applicant, and leading players (by number of patents). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.

One of the key objectives of the report was to estimate the existing market size and the future growth opportunities in DNA synthesis technologies and services market, over the next decade. Based on multiple parameters, such as number of projects and service-based cost distribution we have developed informed estimates on the evolution of the market for the period 2022-2035. The report also features the likely distribution of the current and forecasted opportunity across methods of DNA synthesis (chemical method and enzymatic method), application areas (research & diagnostics and therapeutic applications), company size (small, mid-sized and large) and key geographical regions (North America, Europe and Asia-Pacific and RoW). To account for the future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, portraying different tracks of the anticipated industry’s growth.

The report also features detailed transcripts of interview(s) held with representatives of renowned organizations that are engaged in the DNA synthesis technologies and services industry.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading industry players offering DNA synthesis technologies and services?
  • What are the recent developments and emerging trends in the DNA synthesis technologies and services domain?
  • Which partnership models are commonly adopted by industry stakeholders in the DNA synthesis technologies and services industry? 
  • Which are the leading funding organizations providing grants in the DNA synthesis industry?
  • What is the trend of capital investments in the DNA synthesis technologies and services market?
  • What is the focus of various publications related to DNA synthesis technologies and services? 
  • How has the intellectual property landscape for DNA synthesis technologies and services market evolved over the years?
  • Which factors are likely to influence the evolution of the upcoming DNA synthesis technologies and services market?
  • How is the current and future opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the DNA synthesis technologies and services market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to DNA synthesis technologies. The chapter features a detailed discussion on the components of DNA synthesis, leading and lagging strand synthesis and the chemical and enzymatic method of DNA synthesis. In addition, it discusses the various applications and future prospects of display technologies.

Chapter 4 provides a detailed assessment of the overall landscape of the DNA synthesis technologies and services market, providing information on type of offering, method of DNA synthesis (chemical method and enzymatic method), type of DNA molecule, custom offerings, and application area. Additionally, the report provides information on drug developer(s) involved in the domain, along with analyses based on a number of relevant parameters, such as year of establishment, company size and geographical location of headquarters.

Chapter 5 features elaborate profiles of the key players involved in providing technologies and services for DNA synthesis. Each profile features a brief overview of the company, its financial information, details on its technology / service portfolio, financial information and recent developments and an informed future outlook.

Chapter 6 is a case study featuring a detailed overview of the current market landscape of oligonucleotide manufacturers focused on research and diagnostic applications, based on several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with information on the location of facility (country-wise), regulatory accreditations and certifications received, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, fill / finish, regulatory support, data analytics and reporting, and others) and type of modification(s) offered (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications and others).

Chapter 7  is a case study featuring  a detailed overview of the current market landscape of oligonucleotide manufacturers focused on therapeutic applications, based on several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with information on the location of facility (country-wise), regulatory accreditations and certifications received, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, fill / finish, regulatory support, data analytics and reporting, and others) and type of modification(s) offered (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications and others).

Chapter 8 features an analysis of the partnerships established between various stakeholders in this domain, during the period 2017-2022, covering product development and commercialization agreements, R&D agreements, technology licensing agreements, other licensing agreements, mergers and acquisitions, and other relevant types of deals.

Chapter 9 features a review of the funding and investments made in the domain, in the period between 2017 and 2022, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development. The analysis has been done on the basis of several parameters, such year of funding instances, amount invested, type of funding, leading players and investors, and geographical analysis.

Chapter 10 provides an in-depth analysis of academic grants that have been awarded to various research institutes for projects related to DNA synthesis technologies and services, during the period, 2017- 2022, on the basis of important parameters, such as year of grant award, amount awarded, type of funding institute, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization, study section and type of grant application. The chapter also highlights the popular recipient organizations (in terms of number of grants and amount awarded) and prominent program officers.

Chapter 11 provides a detailed review of more than 12,000 peer-reviewed, scientific articles related to research on DNA synthesis technologies, which have been published between 2017 and 2022, including analysis based on parameters, such as year of publication, key focus area, type of article, popular keywords, popular authors, therapeutic area, geography and key journals (in terms of number of articles published in this domain and impact factor of the journal).

Chapter 12 provides an overview of the various patents that have been filed / granted, since 2017, based on various parameters, such as publication year, geography, CPC symbols, emerging focus areas, type of applicant and leading industry players (in terms of number of patents filed). In addition, the chapter also features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents. 

Chapter 13 includes an insightful market forecast analysis, highlighting growth opportunities of DNA synthesis services market till the year 2035. In addition, we have provided inputs on the likely distribution of the market opportunity based on different method of DNA synthesis (chemical method and enzymatic method), application area (research & diagnostics, and therapeutics applications), company size (small, mid-sized and large) and key geographical regions (North America, Europe and Asia-Pacific and RoW). To account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

Chapter 14 is a summary of the overall report, presenting the insights on the contemporary market trends and the likely evolution of the DNA synthesis services and technologies market.

Chapter 15 is a collection of interview transcript(s) of the discussions held with key stakeholders in this industry.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to DNA Synthesis
3.3. Components of DNA Synthesis
3.3.1. Substrates
3.3.2. Template
3.3.3. Primer
3.3.4. Enzymes
3.3.5. Leading Strand Synthesis
3.3.6. Lagging Strand Synthesis
3.4. DNA Synthesis Technologies
3.4.1. Chemical Method of DNA Synthesis
3.4.2. Enzymatic Method of DNA Synthesis
3.5. Applications of DNA Synthesis
3.6. Future Perspectives

4. MARKET OVERVIEW: DNA SYNTHESIS TECHNOLOGIES AND SERVICES
4.1. Chapter Overview
4.2. DNA Synthesis Technologies and Services: Overall Market Landscape
4.2.1. Analysis by Type of Offering
4.2.2. Analysis by Method of DNA Synthesis
4.2.3. Analysis by Type of DNA Molecule
4.2.4. Analysis by Custom Offerings
4.2.5. Analysis by Application Area

4.3. DNA Synthesis Technologies and Services: Key Industry Players
4.3.1 Analysis by Year of Establishment
4.3.2 Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Application Area and Region

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Ajinomoto Bio-Pharma Services
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Technology / Service Portfolio
5.2.4. Recent Developments and Future Outlook

5.3. ATUM
5.3.1. Company overview
5.3.2. Technology / Service Portfolio
5.3.3. Recent Developments and Future Outlook

5.4. DNA Script
5.4.1. Company Overview
5.4.2. Technology / Service Portfolio
5.4.3. Recent Developments and Future Outlook

5.5. Eurofins Genomics
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Technology / Service Portfolio
5.5.4. Recent Developments and Future Outlook

5.6. Gene Universal
5.6.1. Company Overview
5.6.2. Technology / Service Portfolio
5.6.3. Recent Developments and Future Outlook

5.7. GenScript
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Technology / Service Portfolio
5.7.4. Recent Developments and Future Outlook

5.8. Synbio Technologies
5.8.1. Company overview
5.8.2. Technology / Service Portfolio
5.8.3. Recent Developments and Future Outlook

6. CASE STUDY: OLIGONUCLEOTIDE MANUFACTURERES (RESEARCH AND DIAGNOSTIC APPLICATIONS)
6.1. Chapter Overview
6.2. Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Scale of Operation
6.2.4. Analysis by Geographical Location
6.2.5. Analysis by Location of Manufacturing Facilities
6.2.6. Analysis by Regulatory Accreditations / Certifications Received
6.2.7. Analysis by Type of Oligonucleotide Manufactured
6.2.8. Analysis by Type of Offering
6.2.9. Analysis by Type of Manufacturing Service Offered
6.2.10. Analysis by Type of Modification

7. CASE STUDY: OLIGONUCLEOTIDE MANUFACTURERES (THERAPEUTIC APPLICATIONS)
7.1. Chapter Overview
7.2. Oligonucleotide Manufacturers Focused on Therapeutic Applications: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Scale of Operation
7.2.4. Analysis by Geographical Location
7.2.5. Analysis by Location of Manufacturing Facilities
7.2.6. Analysis by Regulatory Accreditations / Certifications
7.2.7. Analysis by Type of Oligonucleotide Manufactured
7.2.8. Analysis by Type of Offering
7.2.9. Analysis by Type of Manufacturing Service Offered
7.2.10. Analysis by Type of Modification

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. DNA Synthesis Technologies and Services: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Partner
8.3.4. Analysis by Year and Type of Partner
8.3.5. Most Active Players: Analysis by Number of Partnerships
8.3.6. Regional Analysis
8.3.6.1. Intercontinental and Intracontinental Agreements

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. DNA Synthesis Technologies: Recent Funding Instances
9.4. Analysis by Year of Investment
9.5. Analysis by Amount Invested
9.5. Analysis by Amount Invested

9.6. Analysis by Type of Funding and Amount Invested
9.7. Analysis by Venture Capital Funding
9.8. Most Active Players: Analysis by Number of Funding Instances
9.9. Key Investors: Analysis by Number of Funding Instances
9.10. Regional Analysis by Amount Invested
9.11. Funding and Investment Summary

10. GRANT ANALYSIS
10.1 Chapter Overview
10.2. Analysis Methodology and Key Parameters
10.3. DNA Synthesis Technologies and Services: List of Academic Grants
10.3.1. Analysis by Year of Grant Award
10.3.2. Analysis by Grant Amount Awarded
10.3.3. Analysis by Administering Institute Center
10.3.4. Analysis by Support Period
10.3.5. Analysis by Administering Institute Center and Support Period
10.3.6. Analysis by Type of Grant Application
10.3.7. Analysis by Grant Activity Code
10.3.8. Word Cloud of Study Titles
10.3.9. Analysis by Purpose of Grant Award
10.3.10. Popular NIH Departments: Analysis by Number of Grants
10.3.11. Analysis by Type of Recipient Organization
10..12. Prominent Program Officers: Analysis by Number of Grants

11. PUBLICATION ANALYSIS
11.1. Chapter Overview
11.2. Analysis Methodology and Key Parameters
11.3. Analysis by Year of Publication
11.4. Analysis by Quarterly Distribution of Publication
11.5. Analysis by Type of Article
11.6. Analysis by Popular Keywords
11.7. Most Popular Authors: Analysis by Number of Publications
11.8. Popular Publishers: Analysis by Number of Publications
11.9. Popular Journals: Analysis by Number of Publications
11.10. Analysis by Therapeutic Area
11.11. Geographical Analysis

12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Analysis Methodology and Key Parameters
12.3. DNA Synthesis Technologies and Services: Patent Analysis
12.3.1. Analysis by Type of Patent
12.3.2. Analysis by Publication Year
12.3.3. Analysis by Type of Patent and Publication Year
12.3.3. Analysis by Issuing Authority
12.3.4. Analysis by CPC Symbols
12.3.5. Analysis by Type of Applicant
12.3.6. Word Cloud Analysis: Emerging Focus Areas
12.3.7. Leading Industry Players: Analysis by Number of Patents
12.3.8. Leading Non-Industry Players: Analysis by Number of Patents
12.3.9. Leading Players: Analysis by Number of Patents
12.3.10. Leading Patents: International Patents
12.3.11. Analysis by Patent Characteristics
12.3.12. Patent Valuation Analysis

13. DNA SYNTHESIS SERVICES: MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1 Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global DNA Synthesis Services Market, 2022-2035
13.3.1. Global DNA Synthesis Services Market: Distribution by Method of DNA Synthesis, 2022-2035
13.3.2. Global DNA Synthesis Services Market: Distribution by Application Area, 2022-2035
13.3.3. Global DNA Synthesis Services Market: Distribution by Company Size, 2022-2035
13.3.4. Global DNA Synthesis Services Market: Distribution by Geography, 2022-2035

13.4. DNA Synthesis Services Market in North America, 2022-2035
13.4.1. DNA Synthesis Services Market in North America: Distribution by Method of DNA Synthesis, 2022-2035
13.4.2. DNA Synthesis Services Market in North America: Distribution by Application Area, 2022-2035
13.4.3. DNA Synthesis Services Market in North America: Distribution by Company Size, 2022-2035

13.5. DNA Synthesis Services Market in Europe, 2022-2035
13.5.1. DNA Synthesis Services Market in Europe: Distribution by Method of DNA Synthesis, 2022-2035
13.5.2. DNA Synthesis Services Market in Europe: Distribution by Application Area, 2022-2035
13.5.3. DNA Synthesis Services Market in Europe: Distribution by Company Size, 2022-2035

13.6. DNA Synthesis Services Market in Asia-Pacific and Rest of the World, 2022-2035
13.6.1. DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Method of DNA Synthesis, 2022-2035
13.6.2. DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Application Area, 2022-2035
13.6.3. DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Company Size, 2022-2035

14. CONCLUDING REMARKS

15. APPENDIX 1: TABULATED DATA

16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 DNA Synthesis 5’ to 3’
Figure 3.2 DNA Synthesis: Direction of Fork Movement
Figure 3.3 Leading Strand Synthesis
Figure 3.4 Lagging Strand Synthesis
Figure 3.5 Applications of DNA Synthesis
Figure 4.1 DNA Synthesis Technologies and Services: Distribution by Type of Offering
Figure 4.2 DNA Synthesis Technologies and Services: Distribution by Method of DNA Synthesis
Figure 4.3 DNA Synthesis Technologies and Services: Distribution by Type of DNA Molecule
Figure 4.4 DNA Synthesis Technologies and Services: Distribution by Custom Offerings
Figure 4.5 DNA Synthesis Technologies and Services: Distribution by Application Area
Figure 4.6 DNA Synthesis Technologies and Service Providers: Distribution by Year of Establishment
Figure 4.7 DNA Synthesis Technologies and Service Providers: Distribution by Company Size
Figure 4.8 DNA Synthesis Technologies and Service Providers: Distribution by Location of Headquarters
Figure 4.9 DNA Synthesis Technologies and Service Providers: Distribution by Application Area and Region
Figure 5.1 Ajinomoto Bio-Pharma Services: Annual Revenues FY 2018- H1 2021 (JPY Billion)
Figure 5.2 Eurofins Genomics: Annual Revenues FY 2018- FY 2021 (JPY Billion)
Figure 5.3 GenScript: Annual Revenues, FY 2018- H1 2021 (USD Billion)
Figure 6.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
Figure 6.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
Figure 6.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
Figure 6.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Geographical Location
Figure 6.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 6.6 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Regulatory Accreditations / Certifications
Figure 6.7 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured
Figure 6.8 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Offering
Figure 6.9 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size and Type of Offering
Figure 6.10 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering (Custom Synthesis)
Figure 6.11 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Manufacturing Service(s) Offered
Figure 7.1 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment
Figure 7.2 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size
Figure 7.3 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation
Figure 7.5 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Geographical Location
Figure 7.6 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 7.7 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Regulatory Accreditations / Certifications
Figure 7.8 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured
Figure 7.9 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Offering
Figure 7.10 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size and Type of Offering
Figure 7.11 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering (Modification)
Figure 7.13 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Manufacturing Service (s) Offered
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2022
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.4 Partnerships and Collaborations: Distribution by Year and Type of Partner
Figure 8.5 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2017-2022
Figure 8.6 Most Active Players: Distribution by Number of Partnerships
Figure 8.7 Partnerships and Collaborations: Regional Distribution
Figure 8.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 DNA Synthesis Technologies: Cumulative Distribution by Year of Investment, 2017-2022
Figure 9.2 DNA Synthesis Technologies: Cumulative Amount Invested by Year, 2017- 2022 (USD Million)
Figure 9.3 Funding and Investments: Distribution by Type of Funding
Figure 9.4 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 9.5 Funding and Investments: Distribution by Type of Venture Capital Funding
Figure 9.6 Most Active Players: Distribution by Number of Funding Instances
Figure 9.7 Most Active Players: Distribution by Amount Raised, 2017-2022 (USD Million)
Figure 9.8 Funding and Investments: Distribution of Investors by Number of Instances
Figure 9.9 Funding and Investments: Regional Distribution by Amount Invested, 2017-2022
Figure 9.10 Summary of Funding and Investments
Figure 10.1. Grant Analysis: Distribution by Year of Grant Award (FY 2017 – Q1 2022)
Figure 10.2. Grant Analysis: Distribution by Grant Amount Awarded (USD Million)
Figure 10.3. Grant Analysis: Distribution by Administering Institute Center
Figure 10.4. Grant Analysis: Distribution by Support Period
Figure 10.5. Grant Analysis: Distribution by Administering Institute Center and Support Period
Figure 10.6. Grant Analysis: Distribution by Type of Grant Application
Figure 10.7. Grant Analysis: Distribution by Grant Activity Code
Figure 10.8. Word Cloud Analysis: Emerging Focus Areas
Figure 10.9. Grant Analysis: Distribution by Purpose of Grant Award
Figure 10.10. Popular NIH Departments: Distribution by Number of Grants
Figure 10.11. Grant Analysis: Distribution by Type of Recipient Organization
Figure 10.12. Prominent Program Officers: Distribution by Number of Grants
Figure 11.1 Publication Analysis: Cumulative Year-wise Trend, 2017-2022
Figure 11.2 Publication Analysis: Quarterly Distribution of Publications, 2017-2022
Figure 11.3 Publication Analysis: Distribution by Type of Article
Figure 11.4 Word Cloud Analysis: Emerging Focus Areas
Figure 11.5 Analysis by Popular Keywords
Figure 11.6 Most Popular Authors: Distribution by Number of Publications
Figure 11.7 Popular Publishers: Distribution by Number of Publications
Figure 11.8 Popular Journals: Distribution by Number of Publications
Figure 11.9 Publication Analysis: Distribution by Therapeutic Area
Figure 11.10 Publication Analysis: Distribution by Geography
Figure 12.1 Patent Analysis: Distribution by Type of Patent
Figure 12.2 Patent Analysis: Cumulative Distribution by Publication Year (Pre-2017, Q1 2022)
Figure 12.3 Patent Analysis: Year-wise Distribution of Granted Patents, Pre-2017, Q1 2022
Figure 12.4 Patent Analysis: Year-wise Distribution of Filed Patents, Pre-2017, Q1 2022
Figure 12.5 Patent Analysis: Distribution by Type of Patent and Publication Year
Figure 12.6 Patent Analysis: Distribution by Issuing Authority
Figure 12.7 Patent Analysis: Distribution by CPC Symbols
Figure 12.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 12.9 Word Cloud Analysis: Emerging Focus Areas
Figure 12.10 Leading Industry Players: Distribution by Number of Patents
Figure 12.11 Leading Non-Industry Players: Distribution by Number of Patents
Figure 12.12 Patent Analysis: Distribution by Patent Age
Figure 12.13 Patent Analysis: Distribution by Relative Valuation
Figure 13.1 Global DNA Synthesis Services Market: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
Figure 13.2 Global DNA Synthesis Services Market: Distribution by Company Size, 2022-2035 (USD Million)
Figure 13.3 Global DNA Synthesis Services Market: Distribution by Application Area, 2022-2035 (USD Million)
Figure 13.4 Global DNA Synthesis Services Market: Distribution by Geography, 2022-2035 (USD Million)
Figure 13.5 DNA Synthesis Services Market in North America, 2022-2035 (USD Million)
Figure 13.6 DNA Synthesis Services Market in North America: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
Figure 13.7 DNA Synthesis Services Market in North America: Distribution by Application Area, 2022-2035 (USD Million)
Figure 13.8 DNA Synthesis Services Market in North America: Distribution by Company Size, 2022-2035 (USD Million)
Figure 13.9 DNA Synthesis Services Market in Europe, 2022-2035 (USD Million)
Figure 13.10 DNA Synthesis Services Market in Europe: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
Figure 13.11 DNA Synthesis Services Market in Europe: Distribution by Application Area, 2022-2035 (USD Million)
Figure 13.12 DNA Synthesis Services Market in Europe: Distribution by Company Size, 2022-2035 (USD Million)
Figure 13.13 DNA Synthesis Services Market in Asia-Pacific and Rest of the World, 2022- 2035 (USD Million)
Figure 13.14 DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
Figure 13.15 DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Application Area, 2022-2035 (USD Million)
Figure 13.16 DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Company Size, 2022-2035 (USD Million)
Figure 14.1 Concluding Remarks: Overall Market Landscape of DNA Synthesis Technologies and Services
Figure 14.2 Concluding Remarks: Partnerships and Collaborations
Figure 14.3 Concluding Remarks: Funding and Investments
Figure 14.4 Concluding Remarks: Grant Analysis
Figure 14.5 Concluding Remarks: Publication Analysis
Figure 14.6 Concluding Remarks: Patent Analysis

List Of Tables

Table 4.1 DNA Synthesis Technologies and Services: Information on Developers, Type of Offering, Method of DNA Synthesis, Type of DNA Molecule, Custom Offerings and Type of Application Area
Table 4.2 DNA Synthesis Technologies and Services Providers: Information on Year of Establishment, Company Size and Geography
Table 5.1 DNA Synthesis Technology and Service Providers: List of Companies Profiled
Table 5.2 Ajinomoto Bio-Pharma Services: Company Snapshot
Table 5.3 Ajinomoto Bio-Pharma Services: Technology / Service Portfolio
Table 5.4 Ajinomoto Bio-Pharma Services: Recent Developments and Future Outlook
Table 5.5 ATUM: Company Snapshot
Table 5.6 ATUM: Technology / Service Portfolio
Table 5.7 DNA Script: Company Snapshot
Table 5.8 DNA Script: Technology / Service Portfolio
Table 5.9 DNA Script: Recent Developments and Future Outlook
Table 5.10 Eurofins Genomics: Company Snapshot
Table 5.11 Eurofins Genomics: Technology / Service Portfolio
Table 5.12 Gene Universal: Company Snapshot
Table 5.13 Gene Universal: Technology / Service Portfolio
Table 5.14 GenScript: Company Snapshot
Table 5.15 GenScript Technology / Service Portfolio
Table 5.16 GenScript: Recent Developments and Future Outlook
Table 5.17 Synbio Technologies: Company Snapshot
Table 5.18 Synbio Technologies: Technology / Service Portfolio
Table 6.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: List of Industry Players
Table 6.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Location of Manufacturing Facilities and Regulatory Accreditations / Certifications
Table 6.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Oligonucleotide Manufactured and Type of Service(s) Offered
Table 6.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Manufacturing Service(s) Offered
Table 6.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Modification(s) and Type of Purification Method(s) Used
Table 7.1 Oligonucleotide Manufacturers Focused on Therapeutic Applications: List of Industry Players
Table 7.2 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Location of Manufacturing Facilities and Regulatory Accreditations / Certifications
Table 7.3 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Oligonucleotide Manufactured and Type of Offering
Table 7.4 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Manufacturing Service(s) Offered
Table 7.5 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Modification(s) and Type of Purification Method(s) Used
Table 8.1 DNA Synthesis Technologies and Services Providers: List of Partnerships and Collaborations, 2017-2022 (till March)
Table 9.1 DNA Synthesis Technologies: List of Funding Instances, 2017-2022 (till March)
Table 9.2 Funding and Investment Analysis: Summary of Investments
Table 10.1 DNA Synthesis Technologies and Services: List of Academic Grants
Table 12.1 Patent Analysis: CPC Symbols
Table 12.2 Patent Analysis: Most Popular CPC Symbols
Table 12.3 Patent Analysis: List of Top 10 CPC Symbols
Table 12.4 Patent Analysis: List of Relatively High Value Patents
Table 16.1 DNA Synthesis Technologies and Services: Distribution by Type of Offering
Table 16.2 DNA Synthesis Technologies and Services: Distribution by Method of DNA Synthesis
Table 16.3 DNA Synthesis Technologies and Services: Distribution by Type of DNA Molecule
Table 16.4 DNA Synthesis Technologies and Services: Distribution by Custom Synthesis
Table 16.5 DNA Synthesis Technologies and Services: Distribution by Application Area
Table 16.6 DNA Synthesis Technologies and Service Providers: Distribution by Year of Establishment
Table 16.7 DNA Synthesis Technologies and Service Providers: Distribution by Company Size
Table 16.8 DNA Synthesis Technologies and Service Providers Distribution by Location of Headquarters
Table 16.9 DNA Synthesis Technologies and Service Providers Distribution by Application and Region
Table 16.10 Ajinomoto Bio-Pharma Services: Annual Revenues FY 2018- H1 2021 (JPY Billion)
Table 16.11 Eurofins Genomics: Annual Revenues FY 2018- H1 2021 (JPY Billion)
Table 16.12 GenScript: Annual Revenues, FY 2018- H1 2021 (USD Billion)
Table 16.13 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
Table 16.14 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
Table 16.15 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
Table 16.16 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters
Table 16.17 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
Table 16.18 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Regulatory Accreditations / Certifications
Table 16.19 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured
Table 16.20 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Offering
Table 16.21 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size and Type of Offering
Table 16.22 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering (Custom Synthesis)
Table 16.23 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Manufacturing Service(s) Offered
Table 16.24 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment
Table 16.25 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size
Table 16.26 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation
Table 16.27 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters6
Table 16.28 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
Table 16.29 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Regulatory Accreditations / Certifications
Table 16.30 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured
Table 16.31 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Offering
Table 16.32 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size and Type of Offering16
Table 16.33 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering (Modification)
Table 16.34 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Manufacturing Service (s) Offered
Table 16.35 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2022
Table 16.36 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.37 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2017-2022
Table 16.38 Most Active Players: Distribution by Number of Partnerships
Table 16.39 Partnerships and Collaborations: Distribution by Type of Partner
Table 16.40 Partnerships and Collaborations: Distribution by Year and Type of Partner
Table 16.41 Partnerships and Collaborations: Regional Distribution
Table 16.42 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 16.43 DNA Synthesis Technologies: Distribution by Year of Investment, 2017-2022
Table 16.44 DNA Synthesis Technologies: Cumulative Amount Invested by Year, 2017-
2022 (USD Million) 
Table 16.45 Funding and Investments: Distribution by Type of Funding
Table 16.46 Funding and Investments: Distribution of Amount Invested by Type of
Funding (USD Million) 
Table 16.47 Distribution by Type of Venture Capital Funding
Table 16.48 Most Active Players: Distribution by Number of Funding Rounds
Table 16.49 Most Active Players: Distribution by Amount Raised 2017-2022 (USD
Million) 
Table 16.50 Funding and Investment: Distribution of investors by number of instances
Table 16.51 Funding and Investment Analysis: Regional Distribution of Total Amount
Invested, 2017-2022 
Table 16.52 Grant Analysis: Distribution by Year of Grant Award
Table 16.53 Grant Analysis: Distribution by Grant Amount Awarded
Table 16.54 Grant Analysis: Distribution by Administering Institute Center
Table 16.55 Grant Analysis: Distribution by Support Period
Table 16.56 Grant Analysis: Distribution by Administering Institute Center and Support
Year 
Table 16.57 Grant Analysis: Distribution by Type of Grant Application
Table 16.58 Grant Analysis: Distribution by Grant Activity Code
Table 16.59 Grant Analysis: Word Cloud of Study Titles
Table 16.60 Grant Analysis: Distribution by Purpose of Grant Award
Table 16.61 Grant Analysis: Distribution by Type of Recipient Organization
Table 16.62 Popular NIH Departments: Distribution by Number of Grants
Table 16.63 Prominent Program Officers: Distribution by Number of Grants
Table 16.64 Publication Analysis: Cumulative Year-wise Trend, 2017-2022
Table 16.65 Publication Analysis: Quarterly Distribution of Publications
Table 16.66 Publication Analysis: Distribution by Type of Article
Table 16.67 Publication Analysis: Word Cloud of Study Titles
Table 16.68 Analysis by Popular Keywords
Table 16.69 Most Popular Authors: Distribution by Number of Publications
Table 16.70 Popular Publishers: Distribution by Number of Publications
Table 16.71 Popular Journals: Distribution by Number of Publications
Table 16.72 Popular Journals: Distribution by Number of Publications
Table 16.73 Publication Analysis: Distribution by Geography
Table 16.74 Patent Analysis: Distribution by Type of Patent
Table 16.75 Patent Analysis: Cumulative Distribution by Publication Year
Table 16.76 Patent Analysis: Distribution of Granted Patents by Publication Year
Table 16.77 Patent Analysis: Distribution of Filed Patents Publication Year
Table 16.78 Patent Analysis: Distribution by Type of Patent and Publication Year
Table 16.79 Patent Analysis: Distribution by Issuing Authority
Table 16.80 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 16.81 Leading Industry Players: Distribution by Number of Patents
Table 16.82 Leading Non-Industry Players: Distribution by Number of Patents
Table 16.83 Patent Analysis: Distribution by Patent Age
Table 16.84 Patent Analysis: Distribution by Relative Valuation
Table 16.85 Global DNA Synthesis Services Market: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
Table 16.86 Global DNA Synthesis Services Market: Distribution by Company Size, 2022-2035 (USD Million)
Table 16.87 Global DNA Synthesis Services Market: Distribution by Company Size, 2022-2035 (USD Million)
Table 16.88 Global DNA Synthesis Services Market: Distribution by Type of Application Area, 2022-2035 (USD Million)
Table 16.89 Global DNA Synthesis Services Market: Distribution by Geography, 2022-2035 (USD Million)
Table 16.90 DNA Synthesis Services Market in North America, 2022-2035 (USD Million)
Table 16.91 DNA Synthesis Services Market in North America: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
Table 16.92 DNA Synthesis Services Market in North America: Distribution by Type of Application Area , 2022-2035 (USD Million)
Table 16.93 DNA Synthesis Services Market in North America: Distribution by Company Size, 2022-2035 (USD Million)
Table 16.94 DNA Synthesis Services Market in Europe, 2022-2035 (USD Million)
Table 16.95 DNA Synthesis Services Market in Europe: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
Table 16.96 DNA Synthesis Services Market in Europe: Distribution by Type of Application Area, 2022-2035 (USD Million)
Table 16.97 DNA Synthesis Services Market in Europe: Distribution by Company Size, 2022-2035 (USD Million)
Table 16.98 DNA Synthesis Services Market in Asia-Pacific and Rest of the World, 2022- 2035 (USD Million)
Table 16.99 DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
Table 16.100 DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Type of Application Area, 2022-2035 (USD Million)
Table 16.101 DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Company Size, 2022-2035 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. Ajinomoto Bio-Pharma Services
  2. Aldevron
  3. AltaBioscience
  4. Ansa Biotechnologies
  5. Arbor Biosciences
  6. ATUM
  7. Beijing SBS
  8. Bio Basic
  9. Biolegio
  10. Biomatik
  11. Bioneer
  12. Biosearch Technologies
  13. Bio-Synthesis
  14. Blue Heron Biotech
  15. BOC Sciences
  16. BR Biochem Life Sciences
  17. Camena Bioscience
  18. Catalog
  19. ChemGenes Corporation
  20. Creative Biogene
  21. CustomArray
  22. CyberGene
  23. Dalton Pharma Services
  24. DNA Script
  25. Eton Bioscience (Subsidiary of Codex DNA)
  26. Eurofins Genomics
  27. Eurogentec
  28. Evonetix
  29. Futuresynthesis
  30. Gene Universal
  31. General Biosystems
  32. Generi Biotech
  33. Genewiz
  34. GenScript
  35. Glen Research
  36. Helixworks Technologies
  37. IBA Lifesciences
  38. Integrated DNA Technologies
  39. Iridia
  40. KareBay Biochem
  41. Kern Systems
  42. Kilobaser
  43. LC Sciences
  44. metabion
  45. Microsoft
  46. Microsynth
  47. Midland Certified Reagent Company
  48. Molecular Assemblies
  49. Moligo Technologies
  50. Nitto Denko Avecia
  51. Nuclera Nucleics
  52. Oligomer Biotechnology
  53. Origene
  54. ProMab Biotechnologies
  55. ProteoGenix
  56. Quintaribio
  57. Ribbon Biolabs
  58. SARTOMED
  59. Sigma-Aldrich (Acquired by Merck)
  60. Sunomix Biosciences
  61. Synbio Technologies
  62. Syngene
  63. SynHelix
  64. Synthomics
  65. TAG Copenhagen
  66. Thermo Fisher Scientific
  67. Xcelris Labs
  68. Yale School of Medicine
  69. GE Research
  70. Baseclick
  71. French Ministry for Armed Forces
  72. Dynamic Combinatorial Chemistry (DCC)
  73. Bright Peak Therapeutics
  74. Trio Pharmaceuticals
  75. GeneDesign
  76. BIOfidal
  77. Transcenta
  78. Amptec 
  79. Eton Bioscience
  80. Glen Research Corporation
  81. CodexisCodexis
  82. TeselaGen Biotechnology
  83. Analog Devices
  84. imec
  85. LioniX International
  86. PeproTech
  87. Patheon
  88. GSL Biotech
  89. Twist Bioscience
  90. Horizon Discovery
  91. CustomArray
  92. Blue Heron Biotech
  93. SynHelix
  94. Isolere Bio
  95. Aldevron
  96. Biotechnolabs
  97. iGEM
  98. Integrated DNA Technologies
  99. GENEWIZ
  100. Eurofins Genomics
  101. Kazusa DNA Research Institute
  102. GeneBay
  103. Aldevron
  104. Agilent Technologies
  105. Illumina Ventures
  106. Sofinnova Partners
  107. Kurma Partners
  108. Casdin Capital
  109. Danaher Life Sciences
  110. M Ventures
  111. Columbia Threadneedle Investments
  112. Casdin Capital
  113. Alexandria Venture Investments
  114. iSelect Fund
  115. Codexis
  116. Argonautic Ventures
  117. Horizons Ventures
  118. Mubadala Capital
  119. Humboldt Fund
  120. National Science Foundation
  121. Civilization Ventures
  122. Illumina Ventures
  123. Merck Ventures
  124. Idinvest Partners
  125. Bpifrance
  126. Bpifrance
  127. Life Sciences Partners
  128. M. Ventures
  129. Kurma Partners and Idinvest Partners
  130. Bpifrance
  131. Merck 
  132. Life Sciences Partners
  133. Bpifrance
  134. Life Science Partners
  135. Bpifrance Large Venture Fund
  136. Alexandria Venture
  137. Fidelity Management and Research
  138. Arrowmark Partners
  139. Farallon Capital
  140. Moore Strategic Ventures
  141. National Human Genome Research Institute
  142. Coatue Management
  143. Catalio Capital Management
  144. Fidelity Management & Research Company
  145. eureKARE
  146. Irving Investors
  147. IST Cube
  148. tecnet equity
  149. Hadean Ventures
  150. Lansdowne Partners
  151. Helicase Venture
  152. IST cube
  153. tecnet equity
  154. iSelect Fund
  155. Keshif Ventures
  156. Agilent Technologies
  157. LYFE Capital
  158. National Human Genome Research Institute
  159. SynBio Innovation Accelerator
  160. LYFE Capital
  161. DCVC
  162. Rising Tide
  163. Providence Investment Company Limited
  164. Molten Ventures
  165. Cambridge Consultants
  166. Innovate UK
  167. Draper Esprit
  168. The Morningside Group
  169. Providence Investment Company
  170. Cambridge Consultants
  171. Rising Tide Fund
  172. Tech Coast Angels
  173. The Department of Air Force
  174. Department of Health and Human Services
  175. TEEC Angel Fund
  176. TA Associates
  177. Colibri Ventures
  178. Vanderbilt University
  179. Division of Basic Sciences 
  180. Columbia University Health Sciences
  181. Medical College of Wisconsin
  182. Eunice Kennedy Shriver National Institute of Child Health & Human Development
  183. Univ Of North Carolina Chapel Hill
  184. Weill Medical Coll of Cornell Univ
  185. University of Minnesota
  186. University of Iowa
  187. National Institute on Aging
  188. National Institute of Environmental Health Sciences
  189. University of Wisconsin-Madison
  190. Life Technologies
  191. Tosoh
  192. Achillion Pharmaceuticals
  193. Harvard College
  194. Broad Inst

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com